Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of three anesthetic agents—remifentanil, dexmedetomidine, and desflurane—used together to provide balanced anesthesia during surgical procedures. - **Remifentanil** is an ultra-short-acting synthetic opioid analgesic that acts as a potent agonist at the mu-opioid receptor, providing rapid-onset and easily titratable analgesia[2][5]. - **Dexmedetomidine** is a highly selective alpha-2 adrenergic receptor agonist with sedative, anxiolytic, and analgesia-sparing properties; it reduces sympathetic tone and can decrease the need for other anesthetics[10]. - **Desflurane** is a volatile inhalational general anesthetic that induces unconsciousness by enhancing inhibitory neurotransmission (notably via GABA-A receptors) and inhibiting excitatory pathways in the central nervous system[6][9]. The combination leverages synergistic effects to achieve adequate sedation, analgesia, muscle relaxation, hemodynamic stability, and rapid recovery. This regimen may be used in various surgical settings where precise control over anesthesia depth and quick emergence are desired.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on remifentanil + dexmedetomidine + desflurane.